Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid TumorsJoachim Drevs, Clemens Unger, Patrizia Siegert et al.|Journal of Clinical Oncology|2007Cited by 303
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapyJuliane M. Jürgensmeier, Paulo M. Hoff, Jane Robertson et al.|British Journal of Cancer|2013Cited by 64
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumoursHester van Cruijsen, Giuseppe Giaccone, Klaas Hoekman et al.|European Journal of Cancer|2010Cited by 54
An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemiaWalter Fiedler, Hubert Serve, Rolf M. Mesters et al.|Leukemia Research|2009Cited by 42
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapyStuart Spencer, Juliane M. Jürgensmeier, Aurélien Pommier et al.|British Journal of Cancer|2013Cited by 32